This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Morvan syndrome (MoS) is a rare acquired channelopathy associated with autoantibodies against potassium channel complex and clinically characterized by the heterogeneous combination of neuromyotonia, dysautonomia, and encephalopathy.1 Peculiar CNS symptoms are organic insomnia, which ranges from mild to malignant forms characterized by complete loss of sleep, and persistent motor/autonomic hyperactivation (agrypnia excitata2). We describe a patient with MoS who developed progressive agrypnia excitata, in which IV immunoglobulin (IVIg) treatment induced a progressive recovery of the physiologic sleep-wake cycle, documented by videopolysomnography (VPSG) and actigraphic monitoring.
Acknowledgments
Acknowledgment: The authors thank the patient, Francesco Mignani for help in preparing the figures, Elena Zoni for help in preparing the videos, and Cecilia Baroncini for English revision.
Footnotes
↵* All authors contributed equally to this work.
Supplemental data at Neurology.org
Author contributions: Dr. Baiardi: data collection, interpretation of results, preparation of the manuscript. Dr. Provini: data collection, interpretation of results, preparation of the manuscript. Dr. Avoni: data collection, interpretation of results. Dr. Pasquinelli: data collection, interpretation of results. Prof. Liguori: data collection, interpretation of results, preparation of the manuscript.
Study funding: No targeted funding reported.
Disclosure: The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.
- Received December 17, 2014.
- Accepted in final form March 6, 2015.
- © 2015 American Academy of Neurology
AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)
Non-AAN Member subscribers: Sign in with subscriber credentials
Log in using your username and password
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.